The addition of radiation to chemotherapy did not improve overall survival in patients with locally advanced endometrial ...

Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult ...

The European Commission (EC) has approved GSK's Jemperli (dostarlimab) combined with chemotherapy that includes carboplatin ...

Meanwhile, J&J has claimed EU approval for its combination of EGFRxMET bispecific antibody Rybrevant (amivantamab) with third ...

Part of that spike is due to rising rates of cancers that affect primarily women, including breast cancer and endometrial cancer (a.k.a. cancer in the lining of the uterus), Rebecca Siegel, MPH, ...

London: GSK plc has announced the European Commission has approved Jemperli (dostarlimab) in combination with chemotherapy ...

Use of long-acting, reversible contraceptives is associated with an increased risk of certain cancers, a study suggests.

GSK’s Jemperli is designed to help the body’s immune system find and attack cancer cells, and is already approved in the EU ...

Cancer incidence continues to rise for many common cancers—especially for women. The incidence rate for women younger than 50 ...

The risk and incidence of cancer among people under 50 is also on the rise, according to American Cancer Society.

GSK plc (LSE/NYSE: GSK) today announced the European Commission has approved Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult ...

For patients with advanced or recurrent endometrial cancer, first-line Lenvima plus Keytruda didn’t significantly improve ...